Literature DB >> 18465357

Proliferative effects of insulin analogues on mammary epithelial cells.

Doris Mayer1, Ashish Shukla, Harald Enzmann.   

Abstract

Structural modification of insulin results in the generation of insulin analogues that show altered binding affinities to the insulin receptor and/or IGF-I receptor. As a consequence these insulin analogues may have increased mitogenic potency. Nine benign or malignant human mammary epithelial cells, which show different insulin receptor and IGF-I receptor expression patterns, were studied regarding mitogenicity of insulin and insulin analogues. Only insulin glargine showed a significantly higher proliferative effect on MCF-7 breast cancer cells compared to regular insulin among a panel of short- or long-acting insulin analogues, that are in clinical use.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18465357     DOI: 10.1080/13813450801900645

Source DB:  PubMed          Journal:  Arch Physiol Biochem        ISSN: 1381-3455            Impact factor:   4.076


  30 in total

1.  Supramolecular protein engineering: design of zinc-stapled insulin hexamers as a long acting depot.

Authors:  Nelson B Phillips; Zhu-li Wan; Linda Whittaker; Shi-Quan Hu; Kun Huang; Qing-xin Hua; Jonathan Whittaker; Faramarz Ismail-Beigi; Michael A Weiss
Journal:  J Biol Chem       Date:  2010-02-24       Impact factor: 5.157

Review 2.  Pancreatic Cancer and Diabetes Mellitus.

Authors:  Ayush Sharma; Suresh T Chari
Journal:  Curr Treat Options Gastroenterol       Date:  2018-12

3.  Current european regulatory perspectives on insulin analogues.

Authors:  Harald G Enzmann; Martina Weise
Journal:  Diabetol Metab Syndr       Date:  2011-07-07       Impact factor: 3.320

4.  Protected graft copolymer (PGC) basal formulation of insulin as potentially safer alternative to Lantus® (insulin-glargine): a streptozotocin-induced, diabetic Sprague Dawley rats study.

Authors:  Sandra Reichstetter; Gerardo M Castillo; ManShun Lai; Akiko Nishimoto-Ashfield; Aryamitra Banerjee; Alexei Bogdanov; Alexander V Lyubimov; Elijah M Bolotin
Journal:  Pharm Res       Date:  2011-12-28       Impact factor: 4.200

5.  Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study.

Authors:  L G Hemkens; U Grouven; R Bender; C Günster; S Gutschmidt; G W Selke; P T Sawicki
Journal:  Diabetologia       Date:  2009-06-30       Impact factor: 10.122

6.  Diabetes, insulin treatment, and cancer risk: what is the evidence?

Authors:  Madona Azar; Timothy J Lyons
Journal:  F1000 Med Rep       Date:  2010-01-18

7.  Retinal Nerve Fiber Layer Decrease during Glycemic Control in Type 2 Diabetes.

Authors:  Masahiko Sugimoto; Mikio Sasoh; Masashi Ido; Chisato Narushima; Yukitaka Uji
Journal:  J Ophthalmol       Date:  2010-08-08       Impact factor: 1.909

Review 8.  Diabetes and pancreatic cancer.

Authors:  T Muniraj; S T Chari
Journal:  Minerva Gastroenterol Dietol       Date:  2012-12

Review 9.  Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing?

Authors:  Adi J Klil-Drori; Laurent Azoulay; Michael N Pollak
Journal:  Nat Rev Clin Oncol       Date:  2016-08-09       Impact factor: 66.675

10.  Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group.

Authors:  H M Colhoun
Journal:  Diabetologia       Date:  2009-07-15       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.